➤ FDA approves high-dose aflibercept ➤ Positive results in Phase 1 trial for cultivated autologous limbal epithelial cells ➤ Study: data from eye scans detect Parkinson’s disease years before clinical presentation ➤ Phase 2/3 study to evaluate persistent corneal epithelial defect treatment ➤ Phase 3 study offers results with aflibercept biosimilar ➤ ASCRS news and events
➤ FDA approves brolucizumab injection for DME ➤ NDA filed for geographic atrophy drug ➤ Study: Dietary supplements can slow AMD progression ➤ First global study evaluates AI for diabetic retinopathy and referral uptake ➤ Plans to begin two Phase 3 trials for investigational thyroid eye disease therapy ➤ ASCRS news and events
➤ Launch of Phase 3 clinical trial for presbyopia drop candidate ➤ Topline results for investigational dry eye therapy ➤ Positive findings for photobiomodulation dry AMD treatment ➤ Enrollment completed for investigational oral diabetic retinopathy therapy ➤ Longer-term data from Phase 3 studies evaluating geographic atrophy therapy released ➤ Orphan drug designation granted to investigational retinitis pigmentosa treatment ➤ ASCRS news and events